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WereportthemoleculardesignandsynthesisofEG00229,2,thefirstsmallmoleculeligandfortheVEGF-A
receptor neuropilin 1 (NRP1) and the structural characterization of NRP1-ligand complexes by NMR
spectroscopy and X-ray crystallography. Mutagenesis studies localized VEGF-A binding in the NRP1 b1
domainandapeptidefragmentofVEGF-AwasshowntobindatthesamesitebyNMR,providingthebasis
for small molecule design. Compound 2 demonstrated inhibition of VEGF-A binding to NRP1 and
attenuated VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells was
also observed. The viability of A549 lung carcinoma cells was reduced by 2, and it increased the potency of
thecytotoxicagentspaclitaxeland5-fluorouracilwhengivenincombination.Thesestudiesprovidethebasis
for design of specific small molecule inhibitors of ligand binding to NRP1.
Introduction
Neuropilin 1 (NRP1
a)
1 is a receptor for vascular endothelial
growth factor A165 (VEGF-A165) and the neuronal guidance
moleculesemaphorin3A(SEMA3A)
2withkeyrolesinvascular
and neuronal development (Figure 1). In endothelial cells,
NRP1 enhances the biological signals of VEGF-A mediated
by binding to its receptor vascular endothelial growth factor 2
(VEGFR2). NRP1 has also been implicated in tumor growth
and angiogenesis; inhibition by a blocking antibody that pre-
vents VEGF-A binding to NRP1 enhanced the antitumor
effects of the inhibitory anti-VEGF-A antibody, bevacizumab,
in mouse xenograft models.
3 As an alternative to biological
therapeutics,smallmoleculeinhibitorsofNRP1functionwould
be desirable, but development of protein-protein interaction
inhibitors is not a trivial task.
4,5 We utilized the bicyclic peptide
1, corresponding to the C-terminal 28 amino acids of VEGF-
A165 (Figure 2) as a starting point for small molecule design.
From this peptide we developed EG00229, 2(Figure2),asmall
molecule designed to interact with the VEGF-A165 binding
pocket of NRP1. Mutational analysis, NMR, and X-ray crys-
tallography establish that the interaction with NRP1 of peptide
ligands (and by inference VEGF-A) and the new small mole-
cules described herein is with the same binding site formed by
the loops at the end of the b1 domain.
6 These molecules act as
inhibitors of VEGF-A function, reducing VEGF-A receptor
phosphorylation and endothelial cell migration. The in vitro
cytotoxiceffectofpaclitaxeland5-fluorouracilwasenhancedin
the presence of 2. Small molecule inhibitors of NRP1 have
considerable potential as novel anticancer therapeutics.
Results and Discussion
Computational Prediction of the Binding Pocket on NRP1
and Mutational Analysis of VEGF-A Binding. The reported
crystal structures
6,7 and our own computational analysis of the
NRP b1 domain using SYBYL SITEID identified the cleft
formed by the loops at one end of the β-barrel as a potential
binding site (Figure 3a). Residues clustered in this region
8were
conservedinmammalianNRP1speciesandinhumanNRP2,a
closely related receptor for VEGF-A
1 (Figure 3b), implying an
important functional role in VEGF-A binding. Mutational
†Atomic coordinates and structure factors for the reported crystal
structure have been depositedin the Protein DataBank under accession
code 3I97.
*Towhomcorrespondence shouldbeaddressed. Phone:þ44207679
6716. Fax: þ44 207 209 0470. E-mail: d.selwood@ucl.ac.uk.
aAbbreviations: G, glycine; P, proline; A, alanine; V, valine; L,
leucine; I, isoleucine; M, methionine; C, cysteine; F, phenylalanine; Y,
tyrosine; W, tryptophan; H, histidine; K, lysine; R, arginine; Q, gluta-
mine; N, asparagine; E, glutamic acid; D, aspartic acid; S, serine; T,
threonine; bt, biotinylated; Boc, tert-butyloxycarbonyl; BSA, bovine
serumalbumin;DMEM,Dulbecco’smodifiedEagle’smedium;DMSO,
dimethyl sulfoxide; EBM, endothelial cell basal medium; ELISA, en-
zyme-linkedimmunosorbentassay;FBS, fetalbovineserum;FMOC,9-
fluorenylmethyl)oxy]carbonyl; 5-FU, 5-fluorouracil; HEPES, N-2-hy-
droxyethylpiperazine-N0-2-ethanesulfonic acid; HSQC, heteronuclear
single quantumcoherence; HUVECs, human umbilical vein endothelial
cells; NRP1, neuropilin 1; NRP2, neuropilin 2; Pbf, 2,2,4,6,7-penta-
methyldihydrobenzofuran-5-sulfonyl; PBS, phosphate buffered saline;
PyBrOP, bromo-tris-pyrrolidinophosphonium hexafluorophosphate;
PAE, porcine aortic endothelial; SDS, sodium dodecyl sulfate; SE-
MA3A, semaphorin 3A; TIPS, triisopropylsilane; TFA, trifluoroacetic
acid; Tris, tris(hydroxymethyl)aminomethane; VEGF, vascular en-
dothelial growth factor; VEGFR2, vascular endothelial growth factor
receptor 2.2216 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 Jarvis et al.
analysisofVEGF-AbindingtoNRP1wasthereforeperformed
to confirm the identity of the binding pocket. Alanine substitu-
tion of amino acid Y297, W301, T316, D320, S346, T349,
Y353, or W411 resulted in complete loss of high affinity
biotinylated-VEGF-A binding to COS-7 cells transfected with
mutant NRP1 cDNA constructs (Figure 4a). In addition,
alanine substitution of K351 resulted in partial loss of
VEGF-A binding, while mutation of T337, P398, and S416
caused modest decreases in binding and mutation of E319 had
no effect (Figure 4a and Supporting Information Figure S1a).
Loss of binding was not due to impaired expression of NRP1
mutants, as Western blot analysis of transfected COS-7 cells
indicated similar levels of protein expression of all constructs
(Supporting Information Figure S1b). A triple mutant b1
protein (S346A, E348A, T349A) was previously shown to
prevent VEGF-A binding to rat NRP1.
7
NMRStudieswiththePeptide.1,Tuftsin,andAc-DKPRR-
OH Provide Additional Evidence To Identify the NRP1
Binding Pocket for the C-terminus of VEGF-A. The binding
of ligands was assessed by chemical shift perturbation map-
ping with 2D
15N,
1H NMR of
15N-labeled NRP1 b1
(Figure 4b). In each case the residues with significant per-
turbations of the backbone NH cross-peak chemical shifts
were identified (compound Δδ > 0.15; see Experimental
Section). We employed tuftsin as a control ligand for these
studies becauseitsbindingsitehasbeenestablishedbyX-ray
crystallography.
7 Titration with 1, tuftsin (H-TKPR-OH),
and the linear peptide Ac-DKPRR-OH (C-terminal five
residues of VEGF-A) yielded highly similar patterns of
chemicalshiftchangesthatmappedtheVEGF-Ainteraction
site (Figure 4c,d and Supporting Information Figure S2).
The largest chemical shift changes were observed for the
backbone NH groups of W301 (adjacent to C-terminal end
of loop 1); T316, G318, Y322 (loop 5); A344, I345, K347,
T349, K351 (loop 3); and G414, M417 (loop 4) (Supporting
Information Figure S3). The binding site revealed by NMR
was identical to that predicted
6 and previously shown for
tuftsin
7andverysimilartoamapofthekeyresiduesessential
forbinding(Figure4e).Thesedataclearlyindicatethat1and
the peptide Ac-DKPRR-OH bind in a common mode to the
same site as tuftsin and VEGF-A, providing a strong ratio-
naleformodelingtheinteractionofsmallmoleculeinhibitors
with this binding pocket. These data imply that small
molecules blocking this site could interfere with the binding
(and function) of VEGF, and other molecules that bind this
site.
Synthetic Chemistry. Simple linear peptides were synthe-
sized by standard 9-fluorenylmethoxycarbonyl (FMOC)
solid phase methodology as previously reported.
9 For the
small molecules a highly flexible mixed solution phase/solid
phase synthesis was devised that allowed the preparation of
multiple analogues in a timely fashion. The lysine analogue
and linking scaffold were assembled in solution phase and
then coupled in one unit to the arginine-O-Wang resin using
standard coupling conditions (Scheme 1). A representative
example is shown in Scheme 2, which illustrates the range of
chemical manipulations applied to different building blocks.
Thus, Suzuki coupling of 3-nitroiodobenzene 3 with 3-
methyphenylboronic acid 4provided the biphenylderivative
5 which was oxidized to the acid 6 using potassium perman-
ganate. Coupling to preformed Wang-Arg resin with the
reactive coupling agent bromo-tris-pyrrolidinophospho-
nium hexafluorophosphate (PyBrop) gave the nitro com-
pound 7 linked to solid phase. Tin(II) chloride reduction
followed by coupling with the Boc (tert-butyloxycarbonyl)
protectedacidgavetheintermediate8.Thetargetcompound
9 was then produced by deprotection with trifluoroacetic
acid/triisopropylsilane (TFA/TIPS). For further testing lar-
ger amounts of compounds were required, and these were syn-
thesized by solution phase chemistry as shown in Scheme 3
for 2. Reaction of the thiadiazolesulfonyl chloride 10 with
methyl 3-aminothiophene-2-carboxylate 11 was achieved in
pyridine at room temperature to give the sulfonamide 12.
Hydrolysis to the acid 13 with lithium hydroxide and amide
Figure 1. Model for binding of VEGF-A165 to NRP1. NRP1 has a
largeextracellular(Ex)domaincomprisingtandema1/a2,b1/2,and
a c domain, a single membrane-spanning domain, and a small
cytosolic domain (Cyt). The VEGF-A165 C-terminal domain en-
codedbyexons7and8(yellowandblueoblongs,respectively)binds
to the extracellular NRP1 b1 domain. Concomitant binding of the
VEGF homology domain of VEGF-A165 (solid red ovals) to
VEGFR2 results in formation of a receptor complex of NRP1 with
VEGF-A165 and VEGFR2 and enhanced intracellular signaling,
essential for optimal migration and angiogenesis in development
and in tumors.
Figure 2. Bicyclic peptide 1 (C-terminus of VEGF) and small
molecule neuropilin inhibitor 2.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 2217
coupling of 13 with the 2,2,4,6,7-pentamethyldihydrobenzo-
furan-5-sulfonyl (Pbf) protected arginine methyl ester 14
gave 15. Finally deprotection with lithium hydroxide fol-
lowed by TFA and water gave 2.
Design of Small Molecules Mimicking the C-Terminal
Amino Acid Residues of 1. Our strategy for designing
smallmoleculeinhibitorswasinitiallytoperformstructure-
activity relationship studies of short peptides in assays of
VEGF-A binding to porcine aortic endothelial (PAE)
cells expressing NRP1 in the absence of other VEGF recep-
tors (PAE/NRP1) and thereby to identify the essential
properties of peptides necessary for inhibition of binding.
Withthisinformation,wethenconstructedadesigntemplate
for the peptide-NRP1 interaction (Scheme 1, box) and
undertook a systematic search for chemistry scaffolds that
would retain the high affinity of the peptides in binding
assays.
The C-terminal peptide Ac-RXDKPRR
9 of VEGF-A re-
tains significant affinity for NRP1. Substitution of the non-
essential penultimate arginine to alanine 16 and the synthesis
of increasingly N terminal truncated peptides produced
H-KPAR-OH, 17, a minimal length significantly active pep-
tide (Table 1). Substitution with D-amino acids for the lysine
or alanine 18, 19 lowered inhibitory activity. The penultimate
position was tolerant of proline 20 and phenylalanine 21 in
addition to alanine. The terminal arginine was essential for
activity, as replacement with D-arginine 22, lysine 23,o r
glutamine 24 removed activity. The essential C-terminal
arginine was retained with different chemical scaffolds being
used toconnect it tothe lysine (equivalent toK162in VEGF-
A165) (Table 2). These scaffolds were selected on the basis of
an approximate modeling fit of the full small molecule
mimetic with the H-KPAR-OH peptide, and a representative
subset is shown. Biphenyl scaffolds 9, 25, furanylenephenyl
26, and cycloalkylaryl scaffolds 27, 28, 29 gave modest inhi-
bitions.Howeverathiophene-basedscaffold30hadanIC50of
13 μM for inhibition of VEGF-A165 binding to NRP1.
Follow-up studies showed that other five-membered ring
heterocycles were less effective (data not shown). Reversal
ofthesulfonamidelinkage31orreplacementofthethiophene
withaphenylring32removedactivity,asdidremovalofthe4-
aminophenylsulfonamide group 33. The best scaffold exem-
plified by 30 was progressed with an extensive structure-
activity study; salient features are shown (Table 3). Thus,
H-bondacceptorgroupsinthe2or3positionofthearomatic
oraryl groupwerebeneficial, 34and 35, whereasmethylation
of the sulfonamide NH removed activity, 36 and 40.O t h e r4 -
substitutions were tolerated, 37 and 38,w h i l ea
2-nitro group, 39, showed the best activity of the simple
substituents. A fluorinated analogue, 41, was less active.
Insertion of a benzothiadiazole heteroaryl produced com-
pound 2,w i t ha nI C 50 of 8 μM in a cell based assay. The
sulfur atom had a positive effect on potency because the O
analogue42waslessactive.Othersimilarlyactivecompounds
were found, such as 43 and 44. Most alterations to the
arginine, including the unnatural D-enantiomer 45 or 46
(Table 4) or substitution by lysine 47,r e s u l t e di nap a r t i a lo r
complete loss of activity (Table 4). The methyl ester 48 had
poor activity, while replacement of the alkyl side chain by
phenyl, 49, also reduced activity. Extension of the alkyl chain
to four carbons, 50, again reduced activity; however, intro-
ductionofacarbonylgroupintothesidechainofthearginine
51 was partially tolerated. Methylation of the guanidine as in
52orthenitroguanidine53hadpooractivity.Furthermanip-
ulations to the carboxylic acid group in the thiadiazole series,
such asreductiontothe alcohol54or conversion toanamino
acid mimic 55 were deleterious. In contrast the hydroxamic
acid group in 56 was at least partially tolerated . Thus, 2 was
identified asa non-peptide antagonist of VEGF-A binding to
NRP1.
NMR and X-ray Structural Data on 2 Confirm Binding to
the Cleft Formed by the NRP1 Loops and Indicate a Key
Hydrogen Bond in the Structure Stabilizing the Bound Con-
formation. Definitive evidence for the binding site of 2 was
provided by monitoring the NRP1 b1 domain 2D
15N,
1H-
heteronuclear single quantum coherence (HSQC) NMR
Figure 3. (a) VEGF/tuftsin binding site of NRP1 b1 domain (black arrow), with the protein surface and the loops L1 (green), L2 (yellow), L3
(cyan),L4(pink),L5(red),andL6(black)shown.ModelconstructedfromPDBcode2ORZ.(b)Proteinsequencealignmentofhuman,mouse,
and rat NRP1(hNRP1, mNRP1, rNRP1) with humanNRP2 (hNRP2). Highlighted residues werepredicted tobe in close contact with bound
ligand from the model in panel a.2218 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 Jarvis et al.
spectrum in the presence of increasing concentrations of the
ligand.
15N,
1H HSQC spectra are universally used to moni-
torthelocal“chemicalenvironment”ofNHgroups,andina
ligand titration, the exchange regime exhibited by the per-
turbed cross-peaks can be related to the ligand binding
kinetics such that slow-intermediate exchange behavior is
typically observed for ligands with a slow off-rate consistent
with tight binding. Consistent with the measured IC50 for
NRP1 b1 binding, the NMR titration yielded intermediate-
to-slow exchange characteristics for the majority of per-
turbed resonances. Both the distribution of residues that
exhibited ligand-dependent chemical shift perturbations
(Supporting Information Figures S2 and S3) and the direc-
tional pattern of those chemical shift changes (Supporting
Information Figure S4) are highly similar to those obtained
with1,Ac-DKPRR-OH,andtuftsin.Thesedatapointtothe
conservation of interactions between the backbone and side
chain elements of the terminal arginyl moiety of 2 with the
binding pocket on NRP1 b1.
The precise binding mode and ligand conformation of 2
were established by X-ray crystallography of human NRP1
b1. The crystal structure, containing a dimer in the asym-
metric unit (interchain CR root-mean-square deviation of
<0.5 A ˚ ), was determined at 2.9 A ˚ resolution, with electron
density readily observable for 2 in the binding pockets of
both noncrystallographic symmetry related molecules
(Figure 5a). The carboxylate group of 2 superimposes
almost perfectly with the carboxylate group of tuftsin in
the rat NRP1 b1b2 crystal structure (Supporting Informa-
tion Figure S5a).
7 The guanidine groups of the two ligands
also overlay. The structure also reveals an intramolecular
shared hydrogen bond (Figure 5b) between the carbonyl
amide NH and the sulfonamide nitrogen, providing a
stable central conformation of the molecule. We postulate
that this bond is critical for biological activity. In chain A
the benzothiadiazole ring adopts a conformation on the
same side to the guanidine chain with respect to the central
planar portion of the molecule containing the thiophene
ring. In chain B the benzothiadiazole ring is on the opposite
side. In both arrangements the benzothiadiazole ring is
involved in stacking interactions with a side chain residue.
In chain A this interaction is provided by the M276B side
Figure 4. (a) Mutational analysis of the NRP1 pocket. COS-7 cells were transfected with expression plasmids for wild-type (WT)
or mutant NRP1 as indicated. Binding assays using bt-VEGF-A165 were performed 48 h after transfection. Values presented are the
means ( SD obtained from three to six independent experiments each performed in duplicate. (b) An excerpted region of the 2D
15N,
1H
HSQC NMR spectrum of human NRP1 b1 in the free state (black contours) and with saturating concentrations of tuftsin (blue) and
1 (green). The cross-peak assignments for the free-state NRP1 b1 are indicated in bold. Arrows depict significant ligand-dependent
chemical shift changes. (c) Solvent accessible surface representations of the structure NRP1 b1 with color highlighting showing
those residues whose backbone amide NH cross-peak exhibits a significant chemical shift perturbation (compound Δδ >0 . 1 5 ;s e e
Experimental Section) upon addition of a saturating concentration of tuftsin. (d) As for (c) but with 1 as the ligand. The intensity of the
color is scaled to the residue-by-residue value of the compound Δδ. (e) Pymol diagram showing positions of mutated residues on
the NRP1 b1 protein surface. Mutations giving 100% inhibition of binding are shown as red, and moderate inhibition is shown
as salmon (K351).Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 2219
chain of a symmetry related molecule (not shown). In chain
B the benzthiadiazole ring stacks against the N300B side
chain (Supporting Information Figure S5b). The part of the
pocket binding the arginine seems to be an almost perfect
“arginine receptor”, and few changes to the L-arginine were
tolerated.
Binding and Functional Biological Activity of 2 in Endothe-
lial and Lung Carcinoma Cells. Compound 2 selectively
inhibited radiolabeled
125I-VEGF-A binding to PAE/NRP1,
Scheme 1. MixedSolid Phase-Solution Phase Synthetic Strategy
Scheme 2. Typical Analogue Synthesis
a
aReagents: (a) Pd2(dba)3, Pd(PPh3)4, KF, dioxane, reflux 24 h;
(b) KMnO4,p y ,H 2O, reflux 3 h; (c) HOBt, DCI, DMF, Wang-Arg-OH;
(d) SnCl23H2O, DMF; (e) PyBrOP, RCOOH, 2,6-lutidine, CH2Cl2;
(f) TFA, TIPS, H2O.
Scheme 3. Solution Phase Methodology
a
aReagents: (a) pyridine, 20  C; (b) LiOH3H2O, 50  C, THF, MeOH,
H2O; (c) PyBrOP, DIPEA, DCM, 20  C; (d) TFA/H2O 9:1.
Table 1. Establishing Small Peptide Structure-Activity Relationships
a
inhibition of
125I-VEGF binding to
PAE/NRP1 cells
compd structure at 100 μMI C 50 (μM)
16 Ac-RX
bDKPAR-OH 71 ( 6.8% 18 ( 0.11
17 H-KPAR-OH 83 ( 1.2% 30 ( 0.04
18 H-kPAR-OH 51 ( 7.9%
19 H-KPaR-OH 36 ( 5.1%
20 H-KPPR-OH 96 ( 1.2% 14 ( 0.01
21 H-KPFR-OH 63 ( 3.3%
22 H-KPAr-OH 22 ( 9.5%
23 H-KPAK-OH 22 ( 1.2%
24 H-KPAQ-OH 19 ( 7.6%
aIC50 values were measured on all compounds showing inhibition of
>70%. PAE/NRP1 cells in 24-well plates were incubated with different
concentrations (0.1-100 μM) of compounds followed by addition of
0.1 nM
125I-VEGF-A165. Nonspecific binding was determined in the
presence of 100-fold excess unlabeled VEGF. Results were obtained
from three independent experiments, each performed using triplicate
determinations at each concentration of compound, and are presented
as the mean ( SEM. R
2 values ranged from 0.9874 to 0.9996.
bX
is 2-aminobutyric acid.2220 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 Jarvis et al.
but not VEGFR2-expressing cells, with an IC50 of 8 μM
(Table 3) and inhibited bt-VEGF-A binding to purified NRP1
b 1d o m a i ni nac e l l - f r e ea s s a yw i t ha nI C 50 of 3 μM (Figure 6a).
Compound 2 also inhibited VEGF-A binding to lung carci-
nomaA549andprostatecarcinomaDU145cells,whichexpress
NRP1, but not VEGFR1 and VEGFR2, with similar potency
(Supporting Information Figure S6). Binding of VEGF-A to
human umbilical vein endothelial cells (HUVECs), which ex-
press VEGFR2, VEGFR1, and NRP1, was also inhibited by 2
with an IC50 of 23 μM, the reduced potency reflecting the
specificity of 2 for NRP1 and its inability to compete with
VEGF-Abindingtootherreceptors(FigureS6).Thepotencyof
compound 2 in inhibiting VEGF-A binding to NRP1 was thus
very similar to that of the bicyclic peptide compound 1,w h i c h
inhibits
125I-VEGF-A binding to PAE/NRP1 and tumor cells
with IC50 values of 2-3 μM and inhibits
125I-VEGF-A binding
t oH U V E C sw i t ha nI C 50 of 20 μM.
9
The effects of 2 on VEGF-A signaling and function were
examined in human endothelial cells. Compound 2 reduced
VEGF-A-induced VEGFR2 tyrosine phosphorylation in
Table 2. Search for Active Core Scaffolds
a
aIC50 values were measured on all compounds showing inhibition of >70%. PAE/NRP1 cells in 24-well plates were incubated with different
concentrations (0.1-100 μM) of compounds followed by addition of 0.1 nM
125I-VEGF-A165. Nonspecific binding was determined in the presence of
100-fold excess unlabeled VEGF. Results were obtained from three independent experiments, each performed using triplicate determinations at each
concentration of compound, and are presented as the mean ( SEM. R
2 values ranged from 0.9874 to 0.9996.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 2221
HUVECs in a dose-dependent fashion, with a maximum
inhibition of 34% at 100 μM (Figure 6b and Supporting
Information Figure S7). Compound 2 also significantly
reduced VEGF-A induced migration of HUVECs (Figure 6c).
These results agree well with our previous findings showing
partial inhibition of VEGF-A-induced VEGFR2 tyrosine
phosphorylation by the bicyclic peptide NRP1 antagonist
1 and partial inhibition of both VEGFR2 activation
and VEGF-induced migration by an inhibitory NRP1 anti-
body.
3,9 Overall, compound 2 caused a partial inhibition of
VEGF receptor activity and biological function, consistent
with the current model for the role of NRP1 in VEGF
function, in which NRP1 is required for optimal signaling
and certain biological functions downstream of VEGFR2,
particularly migration.
1
The functional effect of 2 was also examined in A549 lung
carcinoma cells, which express NRP1 but no detectable
VEGFR2. Treatment of A549 cells with 2 caused a signifi-
cant reduction in cell viability over a 48 h incubation
(Supporting Information Figure S7). Pretreatment of A549
cellswith2significantlyenhancedthecytotoxiceffectsoftwo
widely used chemotherapeutic drugs, paclitaxel (Figure 6d)
and 5-fluorouracil (Supporting Information Figure S8) by
approximately 4- and 10-fold, respectively. NRP1 down-
regulation by siRNA has previously been shown to increase
the chemosensitivity of pancreatic cancer cells,
10 while cyto-
toxic synergy has been noted for VEGF pathway inhibition
with a combination of the multikinase inhibitor sorafenib
and the proteasome inhibitor bortezomib.
11
Conclusion
Compound 2 exhibited a biological profile consistent with
inhibition of VEGF-A binding to NRP1 demonstrating an
impairment,butnotcompleteinhibition,ofcellmigrationand
VEGFR2 phosphorylation. The viability of carcinoma cells
was also decreased by 2, and it enhanced the potency of
cytotoxics. NRP1 blockers have the potential to target both
angiogenesis and tumor growth and metastasis and may
Table 3. Structure-Activity Relationships for Phenyl Sulfonamides
a
aIC50 values were measured on all compounds showing inhibition of >70%. PAE/NRP1 cells in 24-well plates were incubated with different
concentrations (0.1-100 μM) of compounds followed by addition of 0.1 nM
125I-VEGF-A165. Nonspecific binding was determined in the presence of
100-fold excess unlabeled VEGF. Results were obtained from three independent experiments, each performed using triplicate determinations at each
concentration of compound, and are presented as the mean ( SEM. R
2 values ranged from 0.9874 to 0.9996.2222 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 Jarvis et al.
provide a valuable alternative targeted cancer therapy, parti-
cularly relevant in the light of concern over recent findings
showing that anti-VEGF agents may stimulate metastasis.
12
Compound 2 and its analogues make excellent tools for
the study of NRP1 biology and provide a point of departure
for development of more potent anti-NRP1 drugs in the
future.
Experimental Section
All commercially available solvents and reagents were used
without further treatment as received unless otherwise noted.
NMR spectra were measured with a Bruker DRX 400 or 600
MHz spectrometer; chemical shifts are expressed in ppm relative to
TMS as an internal standard and coupling constants (J)i nH z .
Mass spectra were obtained using a Waters ZQ2000 single quad-
rupole mass spectrometer with electrospray ionization (ESI). High
resolution mass spectra were acquired on a Waters LCT time-
of-flight mass spectrometer with electrospray ionization (ESI).
Analysis of compounds by reverse-phase LCMS was carried out
on an analytical C18 column (Phenomenex Gemini, 50 mm  
3.0mm,5μm)andanABgradientof5-95%forBataflowrateof
1mL/min,whereeluentAwas0.1%formicacid/waterandeluentB
was 0.1% formic acid/acetonitrile. Silica gel (60 A ˚ ,4 0 -63 μm,
Fisher) was used for flash column chromatography. Routine
analytical thin layer chromatography was performed on precoated
plates(60F254,Machery-Nagel).Allcompoundstestedwereatleast
95% pure by LCMS and NMR.
Chemistry. Linear Peptide Synthesis. Linear peptides were
synthesized by Fmoc solid-phase synthesis using Wang or
2-chlorotrityl linkers in accordance with our previously re-
ported methods.
9 The resins and the amino acid derivatives,
Fmoc-Abu-OH, Fmoc(Me)-Ala-OH, Fmoc-Ala-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Boc)-OH,
Fmoc-Phe-OH, and Fmoc-Pro-OH were purchased from
Calbiochem Novabiochem (Nottingham, U.K.) and Bachem
AG (Bubendorf, Switzerland). All solvents used were of
HPLC-grade quality.
Table 4. Structure-Activity Relationships for Arginine Mimetics
a
aIC50 values were measured on all compounds showing inhibition of >70%. PAE/NRP1 cells in 24-well plates were incubated with different
concentrations (0.1-100 μM) of compounds followed by addition of 0.1 nM
125I-VEGF-A165. Nonspecific binding was determined in the presence of
100-fold excess unlabeled VEGF. Results were obtained from three independent experiments, each performed using triplicate determinations at each
concentration of compound, and are presented as the mean ( SEM. R
2 values ranged from 0.9874 to 0.9996.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 2223
Molecular Modeling. Molecules were analyzed using SYBYL
7.0 (Tripos Inc., St. Louis, MO). The Biopolymer tools in SYBYL
were used to build some of the peptides, to check structures for
errors, to correct atom types, and to add/remove hydrogens as
necessary. Structures were minimized using the Tripos force field
with a steepest descent gradient of 100 iterations followed by a
conjugate gradient of 0.01 kcal/mol or a maximum of 10000K
iterations as termination criteria. During minimizations, a 12 A ˚
nonbonded cutoff was applied and when solvent was not present
and ionic strength was set to 4.00. The collected structural data
were analyzed with the graphic tools of SYBYL, version 7.0. All
calculations were performed on the dual Hewlett-Packard work-
station XW6000, two 2.8 GHz CPUs running REDHAT Enter-
prise Linux WS4. The possible binding sites of NRP1 b1 domain
were searched using the SYBYL SITEID module (SYBYL, ver-
sion 7.0; Tripos Inc., St. Louis, MO).
Large Scale Synthesis of 2. 3-(Benzo[1,2,5]thiadiazole-4-sul-
fonylamino)thiophene-2-carboxylic Acid Methyl Ester (12). To a
stirred solution of the arylsulfonyl chloride (10) (7.68 g, 32.7
mmol, 1.2 equiv) in pyridine (30 mL) under nitrogen (balloon)
at 45  C was added dropwise over 1 h a solution of methyl
3-aminothiophene-2-carboxylate (11) (4.28 g, 27.3 mmol, 1 equiv)
in pyridine (10 mL). The resulting suspension was stirred for
20 h at 20  C. The reaction was monitored using TLC and was
deemed complete after approximately 2 h. Water (25 mL) was
added and the resulting mixture stirred for 15 min. The resulting
pale-yellow precipitate was isolated by suction filtration and
w a sw a s h e dw i t hw a t e r( 3  10 mL) followed by isohexane (3  
10 mL), then dried (in vacuo) to afford the desired product. Yield:
9.30 g, 96%. Pale-yellow solid. TLC Rf = 0.2 (ethyl acetate/
isohexane, 1:2). LCMS: tR = 3.09 min; purity >95%. MS: m/z
354.1 [M - 1]
-.
3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)thiophene-2-car-
boxylic Acid (13). The ester 12 (9.28 g, 26.1 mmol, 1 equiv) was
stirred with lithium hydroxide monohydrate (5.48 g, 130.5
mmol, 5 equiv) in a tetrahydrofuran/methanol/water mixture
(5:3:2; 20 mL) at 50  C for 4 h. The reaction mixture was
monitored using TLC; when deemed complete, the solvents
were removed in vacuo. The product was then directly isolated
by precipitation using 2 M hydrochloric acid (100 mL) followed
bysuctionfiltration.Theprecipitatewaswashedwithwater(3 
50 mL) and then with isohexane (3   50 mL) and dried in vacuo
at40 Cfor14htoaffordthedesiredproduct.Yield:8.75g,25.7
mmol, 98%. Beige solid. LCMS: tR = 2.74 min; purity >95%.
MS m/z 340 [M - 1]
-.
1H NMR (400 MHz, DMSO-d6): δ 10.43
(1H,br,s),8.44-8.38(2H,m),7.86(1H,d,J=8.9,7.1Hz),7.75
(1H, d, J = 5.5 Hz), 7.25 (1H, d, J = 5.5 Hz).
(S)-2-{[3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)thiophene-
2-carbonyl]amino}-5-guanidino(Pbf)pentanoic Acid Methyl Es-
ter(15).Theacid(13)(5.0g,14.7mmol,1equiv)andbromo-tris-
pyrrolidinophosphonium hexafluorophosphate (PyBroP, 8.25
g,17.7mmol,1.2equiv)weresuspendedindichloromethane(50
mL),undernitrogen(balloon),andstirredfor2minat20 C.N,
N-Diisopropylethylamine (23 mL, 132.3 mmol, 9 equiv) was
added in one portion and the orange solution stirred at room
temperaturefor10min.Theprotectedaminoacid(H-Arg(Pbf)-
OMe; 8.40 g, 17.7 mmol, 1.2 equiv) was added as a single
portion, and the reaction mixture was stirred at 20  C for 4 h.
The solvent was removed in vacuo and the residue taken up in
ethyl acetate (approximately 200 mL). The solution was washed
with 1 M hydrochloric acid (10   50 mL) and then evaporated
directly to give a viscous brown gum that was maintained under
vacuum for 17 h. The resulting brown glassy solid was carried
forward without further purification. Yield: 11.2 g, 14.7 mmol,
100%. Brown glassy solid. TLC Rf = 0.44 (methanol/ethyl
acetate (10:90)). LCMS tR = 1.81 min; purity >85%.
(S)-2-{[3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)thiophene-
2-carbonyl]amino}-5-guanidino(Pbf)pentanoic Acid. The crude
ester 15 (11.2 g, 14.7 mmol) and lithium hydroxide hydrate (3.08
g, 73.5 mmol, 5 equiv) were stirred in tetrahydrofuran/water (2:1,
300 mL) for 30 min at 20  C. After this time, LCMS indicated
complete reaction, The organic solvent was removed in vacuo and
hydrochloric acid (1 M, aqueous solution, 20 mL) added to
precipitate the product. The resulting solid was collected by
f i l t r a t i o na n dw a s h e dw i t h1Mh y d r o c h l o r i ca c i d( 1 0 0m L ) ,w a t e r
(2 100mL),andisohexane(3 50mL)andthencarriedforward
directly. Yield: quantitative recovery assumed. Yellow solid. Rf =
(ethyl acetate) baseline. LCMS tR = 3.17 min.
1HN M R( 4 0 0
MHz,DMSO-d6):δ11.36(1H,brs),8.42-8.34(3H,m),7.84(1H,
dd,J=8.8and7.0Hz),7.66(1H,d,J=5.3Hz),7.19(1H,d,J=
5.3 Hz), 4.23-4.20 (1H, m), 3.06-3.01 (2H, m), 2.92 (2H, s), 2.46
(3H, s), 2.41 (3H, s), 1.95 (3H, s), 1.82-1.73 (1H, m), 1.69-1.60
(1H, m), 1.40-1.35 (8H, m).
(S)-2-(3-(Benzo[c][1,2,5]thiadiazole-4-sulfonamido)thiophene-
2-carboxamido)-5-guanidinopentanoic Acid (2). The acid (11.0 g,
14.7 mmol, 1 equiv) was stirred with trifluoroacetic acid/water
(9:1,150mL)for65hat25 C.Afterthistimetheacidicsolution
was added to an ice/water mixture, causing the immediate
precipitationofapale-greensolidthatwascollectedbyfiltration
and washed copiously with ether before being suspended in
further ether and subjected to ultrasonic irradiation for ∼5 min.
Theresultingfinepowderwascollectedanddriedundervacuum
at ∼40  C. Yield: 5.16 g, 8.44 mmol, 57%. Pale-green solid.
LCMS tR = 4.77 min; purity >95%. MS m/z 498 [M þ 1]
þ.
1H
NMR (400 MHz, (CD3)2SO/D2O): δ 8.26-8.23 (2H, m), 7.78
(1H,dd,J=8.6and7.0Hz),7.45(1H,d,J=5.3Hz),7.17(1H,
Figure 5. X-ray analysis of 2. (a) FOM weighted difference map of
2-bound NRP1 b1 crystal structure calculated from the model
refined without atomic coordinates for 2. The calculated electron
density (green mesh) clearly shows the presence of the ligand in two
different conformations in the binding sites A and B. Final stick
models for 2 in chain A (left) and chain B (right) are overlaid over
the density. Colors are green, red, blue, and yellow for carbon,
oxygen, nitrogen, and sulfur, respectively. (b) Detail of conforma-
tion of chain A bound 2. The position of the (putative) shared
hydrogen is indicated by a magenta sphere and arrow.2224 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 Jarvis et al.
d, J = 5.3 Hz), 4.26 (1H, dd, J = 9.6 and 4.5 Hz), 3.16-
3.13 (2H, m), 1.88-1.81 (1H, m), 1.77-1.70 (1H, m), 1.60-1.54
(2H,m).
13CNMR(400MHz,(CD3)2SO):δ173.0,163.2,156.8,
154.7, 148.1, 131.9, 130.1, 128.7, 127.0, 119.8, 113.7, 52.0, 40.3,
27.3, 25.4. LCMS: tR = 4.48 min; purity >96%. MS m/z 498
[M þ 1]
þ. HRMS (m/z): [M]
þ calcd for C17H20N7O5S3,
498.0688; found, 498.0697.
Structural Biology Methods. Protein NMR Methods. NMR
spectroscopy was performed at either 500 or 600 MHz
1H
frequency at 25  C.
15No r
13C,
15N-isotope labeled NRP1 b1
sampleswerepreparedin50mMphosphatebufferedsaline(100
mM sodium chloride), 1.0 mM dithiothreitol, 1.0 mM ethyle-
nediaminetetraacetic acid, pH 6.0. Backbone resonance assign-
ments were obtained by analysis of 3D HNCA, HN(CO)CA,
HNCACB, HNCO, HN(CA)CO spectra. Ligand titrations
were monitored by 2D
15N,
1H HSQC spectroscopy of 0.3 mM
NRP1 b1 to which aliquots of buffered ligand (200 mM) were
added until saturation was achieved;
13 the maximal protein
concentration dilution was <10%. Control experiments were
recorded to assess the sensitivity of the NRP1 b1 cross-peak
positions to small changes in protein concentration and sample
pH. NMR spectra were processed with nmrPipe
14 and analyzed
in CCPN analysis.
15 Cross-peak chemical shift perturbations
were declared significant when the compound change in
1H and
15N resonance position Δδ = {[(ΔδN/6.5)
2 þ ΔδH
2]}
1/2 > 0.15
where ΔδN and ΔδH are measured in ppm. Essentially complete
backbone NMR assignments were obtained by standard triple
resonance NMR spectroscopy of a uniformly double
13C,
15N-
isotope labeled sample of NRP1 b1. The pattern of secondary
13C chemical shifts obtained is consistent with the known
globular structure of NRP1 b1 from X-ray diffraction studies,
indicating that the overall structure in solution is unperturbed
(data not shown).
Protein Generation, Purification, and Crystallization with 2.
Recombinant human NRP1-b1 domain was expressed in E. coli
strainRosetta(DE3)(Novagen)asafusionproteincontaininga
tobaccoetchvirusproteasecleavableN-terminalhexahistidinetag.
The protein was purified by combination of immobilized metal
affinity chromatography, size exclusion chromatography (Super-
dex75), and ion exchange chromatography on a SP FF Sepharose
column. Purified NRP1-b1 protein in 20 mM Tris-chloride (pH
7.9) and 50 mM sodium chloride buffer was incubated with a 10-
foldmolarexcessof2for1hat4 C.Theproteinwasconcentrated
to10mg/mLandcrystallizedina1:1volumemixturewith100mM
Figure 6. Binding and functional activity of 2. (a) 2 displaces biotinylated VEGF from NRP1 b1 in a cell-free assay. Plates precoated with
purified recombinant NRP1 b1 domain were incubated for 2 h at room temperature with 0.25 nM bt-VEGF-A165 in the presence of the
indicated concentrations of 2, and specific VEGF binding was determined. Values presented are the means ( SEM obtained from three
independent experiments each performed in triplicate. R
2 = 0.9965. (b) 2 inhibits VEGF-stimulated VEGFR2 phosphorylation. Confluent
HUVECs were pretreated for 30 min with the indicated concentrations of 2 or with an equivalent volume of solvent (DMSO) and were then
treated with or without 25 ng/mL VEGF-A165 for 5 min at 37  C. Total VEGFR2 and VEGFR2 phosphorylated at Tyr1175 were then
determinedintreatedcelllysatesusingaspecificELISA.Valuespresentedarethemeans(SEMobtainedfromthreeindependentexperiments
each performed in duplicate: (/) p < 0.05 versus no 2;( //) p < 0.01 versus no 2;( ///) p < 0.001 versus no 2. (c) 2 decreases chemotactic
responses to VEGF. HUVECs were pretreated for 30 min with the indicated concentrations of 2 or with an equivalent volume of solvent
(DMSO) and placed into top inserts. The chemotaxis of cells toward either VEGF at 25 ng/mL or medium control (C) in bottom wells was
determined after 4 h of incubation. Values presented are the means ( SEM obtained from three independent experiments each performed in
duplicate: (/) p < 0.05 for 100 μM versus 0 μM 2 pretreated cells toward VEGF. (d) Sensitization of carcinoma cells to a chemotherapeutic
agent by2. A549 cells were incubated in serum-free medium containing paclitaxel atthe indicated concentrations in the absence or presence of
100 μM 2. Cell viability was measured after 48 h of treatment. Values presented are the means ( SEM obtained from three independent
experiments each performed in triplicate: (//) p < 0.01 for the chemotherapeutic drug alone versus drug plus 2.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 2225
MES (pH 6.0), 10% PEG 8K, and 200 mM zinc acetate at 20  C
employing hanging drop vapor-diffusion method. Crystals ap-
peared within 3 days, with thick needle morphology and a yellow
hue,fromcompound2.CrystalsbelongedtospacegroupP21with
cell dimensions of a = 40.96 A ˚ , b = 89.60 A ˚ , c = 41.60 A ˚ , R =
90.00 ,β=97.72 ,γ=90.00 andcontainedtwoNRP1-b1mole-
cules in the asymmetric unit.
X-ray Crystallography. A data set at 2.9 A ˚ resolution was
obtained at the London School of Pharmacy by using a R-
AXISIV image plate detector system and Osmic mirrors. Data
were merged and indexed using the program d*TREK
16 in the
CrystalClear
17 software suite. Molecular replacement was per-
formed using PHASER
18 with apo NRP1-b1 domain (PDB
code 1KEX). Iterative rounds of building and refinement were
carried out in COOT
19 and REFMAC5.
20 TLS groups were
generated using the TLSMD Web server.
21 The dictionary file
for 2 was generated using the PRODRG Web server.
22 The
structure was refined to final R/Rfree values of 21.6/28.2% with
reasonable geometry (Table 5).
Plasmids, Adenoviruses, and Mutagenesis. The full-length
open reading frame of human NRP1 (Origene) was cloned into
the pENTR directional TOPO vector. Subsequently plasmid
expression constructs (pcDNA3.2/V5-DEST) and adenoviral
vectors encoding NRP1 constructs (pAd/CMV/V5-DEST) were
generated by LR recombination using the Gateway system
(Invitrogen). Site-directed mutagenesis was performed with the
QuikChange XL site-directed mutagenesis kit (Stratagene). All
constructs were verified by DNA sequencing.
Reagents. Recombinant human VEGF (VEGF-A165) was
obtainedfromR&DSystems(Abingdon,U.K.).Collagentype
I, Dulbecco’s modified Eagle’s medium (DMEM)/25 mM
HEPES, 5-fluorouracil, and paclitaxel were purchased from
Sigma-Aldrich (Dorset, U.K.). All other reagents used were of
the purest grade available.
Cell Culture and Transfection. Human umbilical vein en-
dothelial cells (HUVECs) werepurchased fromTCS CellWorks
(Buckingham, U.K.) and cultured in endothelial cell basal
medium (EBM) supplemented with 10% fetal bovine serum
(FBS), 10 ng/mL human epidermal growth factor, 12 μg/mL
bovine brain extract, 50 μg/mL gentamicin sulfate, and 50 ng/
mL amphotericin-8. Porcine aortic endothelial cells expressing
NRP1(PAE/NRP1)wereprovidedbyDr.ShaySoker.Thecells
were grown in Ham’s F12 medium containing 10% FBS and
25 μg/mL hygromycin B. Human tumor cell lines including
carcinoma lung A549 and prostate DU145 cells were provided
by Quintiles Limited (Edinburgh, U.K.) and grown in RPMI
1640medium(Invitrogen,Paisley,U.K.)containing10%and L-
glutamine. HUVECs or DU145 cells were seeded at the density
of 2   10
4 cells per well of 96-well plates in 0.1 mL growth
medium and transfected with adenovirus vectors containing the
full-length open-reading frame of human NRP1. The adeno-
virus NRP1-transfected cells grew for 2 days prior to a binding
assay. COS7 cells were obtained from ECACC and maintained
in DMEM supplemented with 10% FBS (Invitrogen). COS7
cells were grown in 24-well plates to 80% confluency and
transfected with NRP1 plasmid constructs using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions.
Immunoblotting. Cells were extracted by lysis buffer (64 mM
Tris-HCl, pH 6.8, 0.2 mM Na3VO4, 2% sodium dodecyl sulfate
(SDS), 10% glycerol, protease inhibitors for serine, cysteine,
and metalloproteases). The whole cell lysate samples were
separated by SDS-PAGE and transferred to Immobilon mem-
branes (Millipore). The membranes were immunoblotted with
specific primary antibodies. Immunoreactive bands were visua-
lized by chemiluminescence using horseradish peroxidase-con-
jugated secondary antibodies and enhanced chemiluminescence
reagent (Amersham Biosciences, Bucks, U.K.).
Cell-Based Ligand Binding. Radiolabeled binding displace-
ment experiments were performed in cells grown to confluence
in 24-well plates and using the indicated concentrations of
compounds followed by addition of 0.1 nM
125I-VEGF-A165
(1200-1800 Ci/mmol, GE Healthcare, U.K.) as described pre-
viously(Jiaetal.,2006).
9Nonspecificbindingwasdeterminedin
the presence of 100-fold excess unlabeled VEGF.
Forbiotinylated(bt)-VEGF-A165binding,confluentadenovirus
NRP1-transfected HUVECs or DU145 cells in 96-well plates were
washed twice with phosphate-buffered saline (PBS). The various
concentrations of compounds diluted in binding medium
(Dulbecco’s modified Eagle’s medium, 25 mM N-2-hydroxyethyl-
piperazine-N0-2-ethanesulfonic acid (HEPES), pH 7.3, containing
0.1% bovine serum albumin (BSA)) were added, followed by
addition of 2 nM bt-VEGF-A165.A f t e r2ho fi n c u b a t i o na tr o o m
temperature, the medium was aspirated and washed three times
with PBS. The bound bt-VEGF-A165 to NRP1 was detected by
streptavidin-horseradish peroxidase conjugates and the enzyme
substrate and measured using a Tecan Genios plate reader at 450
nmabsorbancewithareferencewavelengthat595nm.Nonspecific
bindingwasdeterminedinthepresenceof100-foldexcessunlabeled
VEGF-A165. Half maximal inhibitory concentrations (IC50)f o r
selected compounds were obtained from competition curves ob-
tained from
125I-VEGF-A165 and bt-VEGF-A165 binding assays in
which different concentrations (0.1-100 μM) of compound were
tested, using Prism, version 4.0, software and the equation
Y ¼ Bottomþ
ðTop -BottomÞ
1þ10ðlogIC50 -xÞHillslope
where Top and Bottom are the responses, respectively, at the top
and bottom of the curve, Y is the inhibitory response at a given
compound concentration X, and the Hillslope describes the steep-
ness of the curve. R
2 values measuring goodness of fit of the
competitioncurveswerealsodeterminedusingthePrismsoftware.
Cell-Freebt-VEGF-A165Binding.The96-wellplateswerepre-
coated with NRP1-b1 protein at 3 μg/mL overnight at 4  C.
On the following day, the plates were treated with blocking
buffer (PBS containing 1% BSA) and washed three times with
wash buffer (PBS containing 0.1% Tween-20). The various
concentrations of compounds diluted in PBS containing 1%
DMSOwereadded,followedbyadditionof0.25nMbt-VEGF-
A165. After 2 h of incubation at room temperature, the plates
were washed three times with wash buffer. The bt-VEGF-A165
bound to NRP1-b1 was detected by streptavidin-horseradish
peroxidase conjugates and the enzyme substrate and measured
using a Tecan Genios plate reader at 450 nm absorbance with a
Table 5. Data Collection and Refinement Statistics (Molecular Re-
placement)
parameter
space group P21
cell dimension
a, b, c (A ˚ ) 41.0, 89.6, 41.6
R, β, γ (deg) 90, 97.7, 90
resolution (A ˚ ) 30.3-2.9 (3.0-2.9)
a
Rsym or Rmerge 0.079 (0.191)
a
I/σ(I) 8.5 (4.0)
a
completeness (%) 88.0 (85.4)
a
redundancy 2.4 (2.3)
a
Refinement
resolution (A ˚ ) 30.3-2.9
no. reflections 5852
Rwork/Rfree 21.6/28.2
no. atoms
protein 2455
ligand/ion 70
water 8
rms deviation
bond length (A ˚ ) 0.012
bond angle (deg) 1.42
aHighest-resolution shell is shown in parentheses.2226 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 Jarvis et al.
reference wavelength at 595 nm. Nonspecific binding was
determinedintheabsenceofNRP1-b1coatedwellsoftheplates.
Measurement of VEGFR2 Phosphorylation. Following treat-
ment of HUVECs, phosphorylation at Tyr1175 of VEGFR2
and total VEGFR2 in cell lysates were detected by PathScan
phopho-VEGFR2 and total VEGFR2 enzyme linked immuno-
sorbant assay (ELISA) kits (Cell Signalling) according to the
manufacturer’s instructions.
Cell Migration. Cell migration was measured in chemotaxis
24-transwell plates with collagen I-coated inserts incorporating
polyethylene terephthalate track-etched membranes with 8 μm
pores (Becton Dickinson Biosciences). VEGF in EBM/0.1% BSA
wasplacedinthebottomwellsoftheplates.Cellsweretrypsinized,
washed, and resuspended in EBM/0.1% BSA to give a final cell
concentrationof3 10
5/mL.Then1.5 10
5cellswithorwithout2
treatment as indicated were loaded into each top inserts. The
chemotaxis transwell plates were incubated at 37  Cf o r4h .A f t e r
the incubation, nonmigrated cells on the top side of the transwell
membranes were removed and migrated cells on the under side of
the transwell membranes were stained with the REASTAIN
Quick-Diffkit(Reagena,Ltd.,Toivala,Finland). Thestainedcells
from each well were counted in four fields at  100 magnification
using an eyepiece indexed graticule (100 grids).
Cell Viability. Cell viability was determined by measurement
ofconversionofthetetrazoliumsaltXTTtoformformazandye.
Carcinoma cellswere seededata densityof 4 10
3 cellsper well
of 96-well plates in 100 μL of serum-free medium containing
various concentrations of 5-FU or paclitaxel as indicated in the
absence or presence of 2 at 100 μM. After 44 h of incubation,
XTT labeling reagent mixture (Roche Diagnostics, East Sussex,
U.K.) was added to the cultures and they were incubated for a
further4h.Theformazanproductwasthenmeasuredat490nm
with a reference wavelength at 595 nm.
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